Loading...

Ipsen S.A.

IPSEYPNK
Healthcare
Drug Manufacturers - Specialty & Generic
$31.62
$0.48(1.54%)

Ipsen S.A. (IPSEY) Financial Performance & Income Statement Overview

Review Ipsen S.A. (IPSEY) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.

Revenue Growth
8.11%
8.11%
Operating Income Growth
-39.13%
39.13%
Net Income Growth
-46.32%
46.32%
Operating Cash Flow Growth
5.73%
5.73%
Operating Margin
13.90%
13.90%
Gross Margin
82.69%
82.69%
Net Profit Margin
9.68%
9.68%
ROE
8.41%
8.41%
ROIC
10.07%
10.07%

Ipsen S.A. (IPSEY) Income Statement & Financial Overview

Access detailed annual and quarterly income data for Ipsen S.A. IPSEY financial performance.

MetricQ4 2024Q2 2024Q4 2023Q2 2023
Revenue$1.82B$1.75B$1.59B$1.54B
Cost of Revenue$302.00M$316.70M$301.30M$269.90M
Gross Profit$1.52B$1.44B$1.29B$1.27B
Gross Profit Ratio$0.83$0.82$0.81$0.82
R&D Expenses$363.20M$323.40M$329.10M$290.20M
SG&A Expenses$599.30M$574.90M$582.20M$552.70M
Operating Expenses$1.34B$1.12B$818.90M$756.40M
Total Costs & Expenses$1.64B$1.43B$1.12B$1.03B
Interest Income$0.00$5.60M$3.80M$3.00M
Interest Expense$0.00$10.90M$11.20M$15.00M
Depreciation & Amortization$191.10M$160.70M$160.60M$155.60M
EBITDA$709.80M$481.70M$631.30M$480.20M
EBITDA Ratio$0.39$0.27$0.40$0.43
Operating Income$178.90M$317.80M$470.70M$510.30M
Operating Income Ratio$0.10$0.18$0.30$0.33
Other Income/Expenses (Net)-$36.20M-$28.30M$29.40M-$44.50M
Income Before Tax$142.70M$289.50M$500.10M$261.40M
Income Before Tax Ratio$0.08$0.17$0.31$0.17
Income Tax Expense$27.70M$47.20M$80.20M$56.00M
Net Income$113.90M$232.00M$449.20M$195.20M
Net Income Ratio$0.06$0.13$0.28$0.13
EPS$1.37$2.90$1.36$0.59
Diluted EPS$1.37$2.78$1.34$0.59
Weighted Avg Shares Outstanding$83.20M$80.005M$330.56M$330.56M
Weighted Avg Shares Outstanding (Diluted)$83.27M$83.45M$334.05M$332.26M

Financial performance has remained strong, with revenue growing from $1.54B in Q2 2023 to $1.82B in Q4 2024. Gross profit continued to perform well, with margins at 83% in the latest quarter. Operating income reached $178.90M in Q4 2024, holding a steady 10% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $709.80M. Net income dropped to $113.90M, keeping EPS at $1.37. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;